These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 15683685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K, Wiener-Kronish JP, Sawa T.
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [Abstract] [Full Text] [Related]

  • 3. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M, Behrouz B, Norouzi F, Mousavi Gargari SL.
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T.
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [Abstract] [Full Text] [Related]

  • 6. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.
    Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, Frank DW.
    Nat Med; 1999 Apr; 5(4):392-8. PubMed ID: 10202927
    [Abstract] [Full Text] [Related]

  • 7. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T.
    J Infect Dis; 2002 Jul 01; 186(1):64-73. PubMed ID: 12089663
    [Abstract] [Full Text] [Related]

  • 8. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T, Ito E, Nguyen VH, Haight M.
    Hum Vaccin Immunother; 2014 Jul 01; 10(10):2843-52. PubMed ID: 25483637
    [Abstract] [Full Text] [Related]

  • 9. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q, Li H, Zhou J, Zhong M, Zhu D, Feng N, Liu F, Bai C, Song Y.
    Respir Physiol Neurobiol; 2014 Mar 01; 193():21-8. PubMed ID: 24418353
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ, Gerçeker AA, Koles NL, Pollack M, Pier GB.
    Invest Ophthalmol Vis Sci; 1997 Jun 01; 38(7):1418-25. PubMed ID: 9191605
    [Abstract] [Full Text] [Related]

  • 11. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K.
    Vaccine; 2006 Sep 11; 24(37-39):6240-9. PubMed ID: 16806598
    [Abstract] [Full Text] [Related]

  • 12. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, Kohno S.
    Eur Respir J; 2007 May 11; 29(5):965-8. PubMed ID: 17301098
    [Abstract] [Full Text] [Related]

  • 13. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
    Faezi S, Sattari M, Mahdavi M, Roudkenar MH.
    Burns; 2011 Aug 11; 37(5):865-72. PubMed ID: 21334822
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP.
    J Immunol; 2001 Nov 15; 167(10):5880-6. PubMed ID: 11698464
    [Abstract] [Full Text] [Related]

  • 15. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y, Hamaoka S, Kinoshita M, Kainuma A, Shimizu M, Katoh H, Moriyama K, Ishii KJ, Sawa T.
    Microbiol Immunol; 2018 Dec 15; 62(12):774-785. PubMed ID: 30378708
    [Abstract] [Full Text] [Related]

  • 16. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
    Fakoor MH, Owlia P, Mousavi Gargari SL, Sabokbar A.
    Iran J Immunol; 2020 Jun 15; 17(2):121-136. PubMed ID: 32602466
    [Abstract] [Full Text] [Related]

  • 17. A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa.
    Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F.
    mSphere; 2019 Apr 17; 4(2):. PubMed ID: 30996108
    [Abstract] [Full Text] [Related]

  • 18. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.
    Holder IA, Neely AN, Frank DW.
    Infect Immun; 2001 Sep 17; 69(9):5908-10. PubMed ID: 11500471
    [Abstract] [Full Text] [Related]

  • 19. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S, Naito Y, Katoh H, Shimizu M, Kinoshita M, Akiyama K, Kainuma A, Moriyama K, Ishii KJ, Sawa T.
    Microbiol Immunol; 2017 Feb 17; 61(2):64-74. PubMed ID: 28370521
    [Abstract] [Full Text] [Related]

  • 20. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H, Katoh H, Kinoshita M, Shimizu M, Hamaoka S, Akiyama K, Naito Y, Sawa T.
    Microbiol Immunol; 2016 Feb 17; 60(2):114-20. PubMed ID: 26696420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.